Lynch Syndrome is Extremely Unlikely with BRAF Mutation Present
In a colon cancer patient with MLH1/PMS2 loss and a BRAF V600E mutation, Lynch syndrome is extremely unlikely and this almost certainly represents sporadic colorectal cancer. The presence of the BRAF mutation strongly indicates somatic MLH1 promoter hypermethylation rather than a germline mutation 1.
The Diagnostic Algorithm
When MLH1 and PMS2 are both lost on immunohistochemistry, the critical next step is BRAF mutation testing or MLH1 promoter methylation analysis 1. Here's why:
Why BRAF Mutation Excludes Lynch Syndrome
- Approximately 75% of MLH1-deficient colorectal cancers are sporadic, not Lynch syndrome 1
- BRAF V600E mutations occur in sporadic cancers that develop through the CpG island methylator phenotype pathway, causing somatic (acquired) MLH1 promoter hypermethylation 2
- BRAF mutations are predominantly found in sporadic CRC and are virtually absent in Lynch syndrome 2, 3, 4
The Evidence Supporting This Approach
The AGA guidelines explicitly state that when BRAF mutation testing is positive in an MLH1-deficient tumor, Lynch syndrome is extremely unlikely 1. Multiple research studies confirm this:
- One study found BRAF mutations in 0% of confirmed Lynch syndrome cases but in 73-77% of sporadic MSI-high cancers with MLH1 loss 5, 3
- Another study analyzing 11 confirmed Lynch syndrome cases found all were BRAF wild-type 3
- A large screening study of 1,403 colorectal cancers found that all 11 proven Lynch syndrome cases were BRAF-negative 4
The Critical Caveat
However, BRAF testing is not 100% specific. The AGA guidelines acknowledge that BRAF mutations and MLH1 hypermethylation are found in some patients with Lynch syndrome, though this represents no more than 10% of cases and likely substantially fewer 1. This means:
- The vast majority of BRAF-positive, MLH1-deficient tumors are sporadic
- A small minority (<10%) could theoretically still be Lynch syndrome
- The guidelines accept this small miss rate given the cost and anxiety of universal germline testing
Practical Management Recommendation
For this patient, no germline genetic testing is recommended based on current guidelines 1. The BRAF mutation serves as a "second-stage" tumor test that effectively rules out Lynch syndrome with high confidence.
If you want absolute certainty, you could proceed to germline MLH1 testing, but this is not the standard approach and would be considered over-testing in most circumstances. The guidelines specifically recommend against proceeding directly to germline testing when BRAF is positive 1.
When to Reconsider
You should reconsider Lynch syndrome if:
- Strong family history meeting Amsterdam criteria despite BRAF positivity
- Very young age of onset (<30 years)
- Multiple Lynch-associated cancers in the patient
- Clinical suspicion remains extremely high despite molecular findings
In such exceptional cases, genetic counseling and possible germline testing could be considered despite the BRAF mutation, acknowledging the rare possibility of a false-negative screening result.